These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 9263656)

  • 1. Antiplatelet and antithrombin therapies in the acute coronary syndromes.
    Alexander JH; Harrington RA
    Curr Opin Cardiol; 1997 Jul; 12(4):427-37. PubMed ID: 9263656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future perspectives on antithrombin and antiplatelet therapies: novel antiplatelet and antithrombin therapies.
    Kandzari DE
    Rev Cardiovasc Med; 2006; 7 Suppl 3():S43-52. PubMed ID: 17228270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet agents in acute coronary syndromes.
    Eikelboom JW; Anand S
    Semin Vasc Med; 2003 Nov; 3(4):403-14. PubMed ID: 15199447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The scientific basis for combined platelet and thrombin-directed pharmacotherapy in acute coronary syndromes.
    Becker RC
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E19-24;discussion E25-8. PubMed ID: 11156725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Glycoprotein 2b3a inhibitors for acute coronary syndromes: what the trials tell us].
    Elian D; Guetta V
    Harefuah; 2003 May; 142(5):350-4, 398. PubMed ID: 12803058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New therapeutic prospects in acute coronary thrombosis].
    Roux S
    Arch Mal Coeur Vaiss; 1995 Jan; 88(1):91-4. PubMed ID: 7646255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein IIb/IIIa antagonists: do they have a role in the management of unstable angina?
    Redwood S; Marber M; Jackson G
    Int J Clin Pract; 1999 Dec; 53(8):618-22. PubMed ID: 10692757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current antiplatelet therapies: benefits and limitations.
    Angiolillo DJ; Guzman LA; Bass TA
    Am Heart J; 2008 Aug; 156(2 Suppl):S3-9. PubMed ID: 18657680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of cardiovascular events after acute coronary syndrome.
    Wallentin L
    Semin Vasc Med; 2005 Aug; 5(3):293-300. PubMed ID: 16123917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the pathogenesis and treatment of acute coronary syndromes.
    Thompson CA; Danzell JD; Hanley HG
    J La State Med Soc; 1999 May; 151(5):272-7. PubMed ID: 10363482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE).
    Budaj A; Brieger D; Steg PG; Goodman SG; Dabbous OH; Fox KA; Avezum A; Cannon CP; Mazurek T; Flather MD; Van De Werf F;
    Am Heart J; 2003 Dec; 146(6):999-1006. PubMed ID: 14660991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of platelet antiaggregating agents in acute coronary syndromes].
    Torres Peláez Mde L; Santiago Arana C
    Arch Cardiol Mex; 2002; 72 Suppl 1():S291-5. PubMed ID: 12001865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies in the management of acute coronary syndromes.
    Fullwood J; Butler G; Smith T; Cox M; Bride W; Mostaghimi Z; Cook PS; Granger BB
    Nurs Clin North Am; 2000 Dec; 35(4):877-95. PubMed ID: 11072276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic and antiplatelet therapies in relation to risk stratification in patients with non-ST elevation acute coronary syndrome: insights from the Sino-Global Registry of Acute Coronary Events.
    Zhang LJ; Chen YD; Song XT; Zhao FH; Lü SZ
    Chin Med J (Engl); 2009 Mar; 122(5):502-8. PubMed ID: 19323898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
    Faxon DP
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition.
    Ferguson JJ; Waly HM; Wilson JM
    Eur Heart J; 1998 Apr; 19 Suppl D():D3-9. PubMed ID: 9597517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.